|Articles|October 28, 2009
Rules Based Medicines Launches CardiovascularMAP
Advertisement
Based on RBM’s proprietary Multi-Analyte Profiling (MAP) platform, CardiovascularMAP is designed to advance the development of drugs for cardiovascular disease. Pharmaceutical and biotechnology groups collaborated to design the tool, which combines common biomarkers with additional ones to identify new patterns of disease.
"RBM is providing access to the most comprehensive array of cardiovascular biomarkers ever
assembled in one panel,” said George P. Rodgers, MD, FACC, past chairman of the
American College of Cardiology Board of Governors, in a press release. “Accurate measurement of these
biomarkers clearly has the potential to accelerate CVD research programs."
assembled in one panel,” said George P. Rodgers, MD, FACC, past chairman of the
American College of Cardiology Board of Governors, in a press release. “Accurate measurement of these
biomarkers clearly has the potential to accelerate CVD research programs."
For more information, click here .
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
- Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025
- Latest NIMBLE Study Results Highlight Progress in gMG Research
September 12th 2025
Advertisement
Advertisement